Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769381 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL14464261 | 1.00 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL14143937 | 0.92 | SLC5A1 (0.75) | SLC5A2SLC5A1 | |
| SCHEMBL3770149 | 0.92 | SLC5A1 (0.75) | SLC5A2SLC5A1 | |
| SCHEMBL12589161 | 0.92 | SLC5A1 (0.55) | SLC5A2SLC5A1 | |
| SCHEMBL5511109 | 0.92 | SLC5A1 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL3764436 | 0.92 | SLC5A1 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL14182119 | 0.91 | SLC5A1 (0.63) | SLC5A2SLC5A1 | |
| SCHEMBL2050859 | 0.91 | SLC5A2 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL3770929 | 0.91 | SLC5A2 (0.64) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO., INC. (JP) | 2010-03-11 | — | — | US | claimed |
| EP-1338603-B1 | NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME | AJINOMOTO KK (JP) | 2010-01-20 | — | — | EP | claimed |
| US-7645787-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2010-01-12 | — | — | US | claimed |
| US-20070270479-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO. INC (JP) | 2007-11-22 | — | — | US | claimed |
| US-6815428-B2 | AS DIABETIC-MEDICINE WHICH IS EASY TO SYNTHESIZE, LESS TOXIC AND HAS HIGHER CURATIVE EFFECT | AJINOMOTO CO., INC. (JP) | 2004-11-09 | — | — | US | claimed |
| US-20040006025-A1 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2004-01-08 | — | — | US | claimed |
| EP-1338603-A1 | NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2003-08-27 | — | — | EP | claimed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| EP-2163555-A1 | New pyrazole derivatives and diabetic medicine containing them | Ajinomoto Co., Inc. (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO., INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-1338603-B1 | NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME | AJINOMOTO KK (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-7645787-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070270479-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO. INC (JP) | 2007-11-22 | — | — | US | disclosed |
| US-7015201-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20060058244-A1 | New pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2006-03-16 | — | — | US | disclosed |
| US-20050143424-A1 | Prophylactic and therapeutic agent of diabetes mellitus | AJINOMOTO CO. INC (JP) | 2005-06-30 | — | — | US | disclosed |
| US-20050043249-A1 | New pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1500403-A1 | PREVENTIVE/REMEDY FOR DIABETES | Ajinomoto Co., Inc. (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-6815428-B2 | AS DIABETIC-MEDICINE WHICH IS EASY TO SYNTHESIZE, LESS TOXIC AND HAS HIGHER CURATIVE EFFECT | AJINOMOTO CO., INC. (JP) | 2004-11-09 | — | — | US | disclosed |
| US-20040006025-A1 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006025-A1 | Pyrazole derivatives and diabetic medicine containing them | SLC5A2, SLC5A1, DPP4 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20070270479-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885 |
| US-20060058244-A1 | New pyrazole derivatives and diabetic medicine containing them | DPP4, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885 |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885 |
| US-20050043249-A1 | New pyrazole derivatives and diabetic medicine containing them | DPP4, SLC5A2, SLC5A1 | SLC5A2 2/4885SLC5A1 3/4885 |
| US-20050143424-A1 | Prophylactic and therapeutic agent of diabetes mellitus | SLC5A2, SLC5A1, GPR119 | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.